Super-Bond is made up of a polymerization initiator, a liquid and a polymer powder
Brazil has the 4th largest pet market in the world with an estimated market size of BRL 1.8 billion, growing annually at 16%
Lupin had earlier received the U.S. FDA acceptance of the Biologics License Application (BLA) for Its proposed biosimilar
The manufacture of finished doses will commence in 2022 and at full operational capacity, the annual production is expected to exceed 100 million doses annually
The approval allows it to market its products in the country
Biocon Pharma will be responsible for drug development and manufacturing, while Libbs will leverage its deep expertise and reach in Brazil to import, distribute and market
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
This certification validates the plant’s robust capabilities in manufacturing a wide range of sterile dosage forms
The audit has been concluded with no major observations
Subscribe To Our Newsletter & Stay Updated